Press Release April 27, 2020

COMPASS Completes $80 Million Series B

The London Life Sciences team advised COMPASS Pathfinder Holdings Limited (“COMPASS”) on the successful completion of its $80 million Series B round. The round was led by the McQuade Center for Strategic Research and Development LLC  (a member of the global Otsuka family of pharmaceutical companies), Founders Fund and existing investor ATAI Life Sciences, along with investment from other new investors including Perceptive Advisors, Able Partners, Camden Partners Nexus, Skyviews Life Science, and Soleus Capital.
 
COMPASS is a mental health care company dedicated to accelerating patient access to evidence based innovation in mental health. Their first major initiative is developing psilocybin therapy for patients with treatment resistant depression.
 
The Goodwin team was led by Sophie McGrath, Lucy Thomas and Mitchell Bloom.
 
For more information on the financing, please read the press release.